TNFRSF8 anticorps (PE)

N° du produit ABIN2663333

Détail du produit anti-TNFRSF8 anticorps (PE)

Antigène: TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF8 est conjugé à/à la PE

Application: Immunofluorescence (IF), Western Blotting (WB)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: BY88

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TNFRSF8

Antigène: TNFRSF8 (Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8))

Autre désignation: CD30 (TNFRSF8 Produits)

Synonymes: anticorps CD30, anticorps D1S166E, anticorps Ki-1, anticorps Cd30, anticorps Ki, anticorps TNFRSF8, anticorps TNF receptor superfamily member 8, anticorps tumor necrosis factor receptor superfamily, member 8, anticorps TNFRSF8, anticorps Tnfrsf8

Sujet: CD30, also known as Ki-1 antigen, lymphoid activation antigen CD30, and tumor necrosis factor receptor superfamily member 8 is a type I transmembrane receptor that contains four TNF receptor domains with an approximate molecular weight of 64 kD. CD30 is highly expressed on Hodgkins and Reed-Sternberg cells as well as activated, but not resting, T and B cells. CD30 has been shown to interact with a number of proteins including TRAF1, TRAF2, TRAF3, TRAF5, NPM-ALK, TRAF-interacting protein, and CD30 ligand (CD153). Signaling through CD30 is thought to limit the proliferative potential of autoreactive CD8 effector T cells and protect against autoimmunity.